Introduction {#Sec1}
============

It has been estimated that around 422 million adults worldwide were living with diabetes in 2014, representing an increase in prevalence of 3.8% from 1980 in the adult population \[[@CR1]\]. The majority of these cases represent type 2 diabetes (T2D) and reflect the increased prevalence of risk factors, which include an aging population, the current obesity epidemic, and lifestyle factors such as an unhealthy diet, physical inactivity, and smoking \[[@CR1]\]. Patients with T2D have an increased risk of cardiovascular and cerebrovascular morbidity and mortality, as well as other diabetes-associated complications such as visual impairment, renal failure, and lower-limb amputations. Achieving and maintaining glycemic control reduces the long-term risk of microvascular complications \[[@CR2]\]; however, despite the availability of detailed management guidelines \[[@CR2]--[@CR6]\] and a wide range of treatment options, almost half of patients with diabetes in the USA fail to achieve adequate glycemic control, defined by a glycated hemoglobin A1c (HbA1c) level \< 7% \[[@CR7]\].

Protracted failure to achieve glycemic targets as a result of delayed insulin initiation puts patients at risk of diabetes-associated complications and premature death \[[@CR8]\]. Among patients who fail to meet glycemic goals, a substantial proportion experience clinical inertia (a delay in treatment intensification despite suboptimal glycemic control). Clinical inertia is not only a problem among patients who are yet to initiate injectable therapy but also for those who require further intensification following commencement of injectable therapy, with median times to initiate and intensify insulin therapy of several years \[[@CR9], [@CR10]\].

Clinical inertia is multifactorial, with contributory factors from patients and clinicians. These include fear of hypoglycemia \[[@CR11]\], concerns regarding weight gain, and the perceived complexity of insulin regimens, which impact patients' day-to-day lives and clinicians' resources, leading to poor adherence \[[@CR11]\]. From the patient's perspective, injectable therapy is associated with the belief that their diabetes is worsening \[[@CR12]\]. In addition, physicians may lack the support, knowledge, and training necessary to optimally manage T2D, for which there has been a rapid increase in treatment options within a relatively short period of time, alongside changes in the recommended approach to patient management. For example, the emphasis on individualization of treatment goals and therapy choice in treatment guidelines could paradoxically encourage clinical inertia because no clear recommendations as to how to achieve this personalization are given \[[@CR8]\].

Today, the majority of patients with T2D are managed in primary care settings. However, as the incidence of T2D increases, it is likely that physicians will have less time to manage patients in an optimal manner \[[@CR13]\]. Therefore, there is a need to encourage the involvement of other healthcare professionals in patient-facing roles across all settings, who may be in a unique position to provide support in the management of these patients, either as independent practitioners or as part of a multidisciplinary team. This may help ensure optimal therapy is initiated and maintained in a timely manner for individual patients. In this narrative review, we outline the important role that pharmacists can play in diabetes care, briefly summarize the main advantages and disadvantages of the different types of basal insulins, and provide information on titration, with a focus on the newer longer-acting basal insulins. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Role of the Pharmacist in Diabetes Care {#Sec2}
=======================================

Pharmacists play an integral role in the healthcare delivery system in the USA and are one of the most accessible healthcare professionals in most communities \[[@CR14]\]. A meta-analysis comparing prescribing practices for the management of acute and chronic health conditions in primary and secondary care found that non-physician prescribers (e.g., nurse practitioners, pharmacists, and physician assistants) were as effective as physician prescribers, delivering comparable outcomes across a range of indices, including HbA1c control, medication adherence, patient satisfaction, and health-related quality of life \[[@CR15]\]. Moreover, patients with diabetes see their pharmacists on average seven times more often than they see their primary care physician \[[@CR14]\], placing patient-facing pharmacists in a unique position to provide education and care.

The beneficial impact of pharmacists' involvement specifically in the management of diabetes was demonstrated in a meta-analysis of 14 studies comprising 2073 patients, which showed statistically and clinically significant associations between pharmacist intervention and improvements in both HbA1c and fasting plasma glucose (FPG) \[[@CR16]\]. A retrospective chart review revealed that referral to a medication-therapy management and education service provided by clinical pharmacists resulted in a statistically significant reduction in HbA1c and an increase in the number of patients achieving HbA1c \< 7% \[[@CR17]\]. Pharmacist-managed diabetes care services can also improve screening rates and achievement of glycemic and lipid goals \[[@CR18]\]. In a randomized controlled trial, pharmacist intervention led to significant improvements in HbA1c and was particularly beneficial when patients switched the type and/or dose of antihyperglycemic agents \[[@CR19]\].

Pharmacists' roles are increasingly moving beyond the more traditional aspects of screening, education, and monitoring. Within the Veterans Health Administration, clinical pharmacist specialists (CPSs) have independent prescriptive authority to provide comprehensive medication management for patients with chronic diseases, including diabetes, and play an active role not only in prescribing antihyperglycemic agents but also in addressing adverse events such as hypoglycemia \[[@CR20]\]. CPS-led therapeutic monitoring clinics can have a significant beneficial impact on glycemic control for patients living in rural areas with limited access to medical facilities. A retrospective chart review found that veterans with HbA1c ≥ 8% who were referred to a CPS-managed clinic and persisted with their visits showed significant HbA1c reductions, with 74% achieving HbA1c \< 8%. The veterans also showed significant improvements in diastolic blood pressure, total cholesterol, and triglyceride levels \[[@CR21]\]. In a rural area, remote intervention using a real-time, clinic-based video program led by a CPS also resulted in a significant decrease in HbA1c and in an increased number of veterans achieving glycemic goals after 6 months, with patients reporting a high level of satisfaction with the service \[[@CR22]\]. Finally, a recent meta-analysis of 11 studies evaluating the effects of community pharmaceutical care and therapy management services for patients with diabetes further showed, in addition to improvements in glycemic control, the effectiveness of a wide range of patient-centered and interdisciplinary interventions led by pharmacists, which included providing feedback to clinicians, defining individualized glycemic targets, and checking the patients' level of knowledge of their treatment regimens \[[@CR23]\]. The practice setting in this specific meta-analysis is of particular relevance because most of the studies assessed the role of clinical/hospital pharmacists as opposed to community pharmacists \[[@CR16]\], although the sample size was relatively small \[[@CR23]\]. It should be noted that two out of six studies in the community setting for which HbA1c data were available included patients on insulin therapy \[[@CR23]\].

Perhaps one of the most important periods when a patient with diabetes requires support is during the initiation and titration of basal insulin. A retrospective cohort study in the USA showed that, compared with physician management alone, a pharmacist-managed insulin-titration program resulted in significantly greater HbA1c reductions, with a greater proportion of patients adhering to recommended preventive care measures \[[@CR24]\]. Although guidelines state that most patients can be taught to titrate their own insulin dose using simple algorithms, they also point out that frequent contact may be necessary during this period \[[@CR2]\]. The findings of the aforementioned study show that pharmacists are well placed to offer support, for example, helping to ensure that patients understand their medication and titration schedule and checking for hypoglycemia. In addition, a study assessing the impact of pharmacist-led face-to-face initiation and titration of basal insulin in a Veterans Affairs Health Care System, using a pre-planned protocol, resulted in improvement in patient glycemic control \[[@CR25]\]. Similarly, a study of community pharmacies in Canada showed that independent prescribing, initiation, and titration of insulin by pharmacists resulted in an HbA1c reduction from 9.1% to 7.3% over 26 weeks \[[@CR26]\]. Other studies on pharmacist-led titration services in the USA showed similar positive impacts on glycemic control; significant improvements in HbA1c were seen with pharmacist-managed insulin titration compared with standard care in underserved patients with T2D \[[@CR27]\] and with titration-by-phone as part of the pharmacy services in a family medicine department \[[@CR28]\].

An adequate insulin dosing process is thus essential for optimal clinical outcomes. If patients do not receive support during titration they may skip doses or stop taking insulin altogether. Pharmacists can develop protocols for more frequent follow-ups to ensure better titration. In addition, they can ensure that insulin titration is proceeding according to the guidelines in a safe, effective, and evidence-based manner (i.e., asking patients about their glycemic goals whenever they refill a prescription and if they are taking the adequate doses, making sure they understand the dose titration schedule, inquiring about their injection techniques and blood glucose measurement practices, and asking about hypoglycemia) \[[@CR29]\].

Therefore, pharmacists need to be well versed in the types of insulin available and their pros and cons, as well as the guidelines and process of basal insulin initiation and titration and the potential issues that may arise, complementing the role of healthcare providers in the control of hyperglycemia and the monitoring of insulin therapy.

Insulin Formulations in the Management of T2D {#Sec3}
=============================================

T2D is a progressive disease; as β-cell function declines, escalation of treatment with oral antidiabetes drugs (OADs) becomes less effective, and ultimately insulin therapy becomes a major means of controlling hyperglycemia. Treatment guidelines recommend starting insulin treatment with basal insulin, usually in combination with metformin \[[@CR4], [@CR5]\], supporting the initiation of insulin at multiple junctures of the treatment algorithm in patients with HbA1c ≥ 9%, in dual- and triple-therapy regimens, and as a combination with non-insulin injectable agents \[[@CR5], [@CR6]\].

In the USA, practitioners have a number of different options: intermediate-acting neutral protamine Hagedorn (NPH) insulin, long-acting basal insulin analogs (insulin glargine 100 U/mL \[Gla-100\] and insulin detemir \[IDet\]), and second-generation basal insulin analogs (insulin glargine 300 U/mL \[Gla-300\], insulin degludec 100 U/mL \[IDeg-100\], and insulin degludec 200 U/mL \[IDeg-200\]). There are also fixed-ratio combinations of basal insulins and glucagon-like peptide-1 receptor agonists available; however, our current discussion focuses solely on basal insulins. Information on the available basal insulins is presented in Table [1](#Tab1){ref-type="table"}.Table 1Summary of basal insulin product characteristicsProductOnset (h)Duration (h)Dosage forms and strengthsInsulin units per vial/penMaximum single-injection dose for pen devices (U)Median cost \[[@CR6]\]^a^ (USD)Storage days at room temperature (in use)Insulin glargine 100 U/mL \[[@CR30]\]2--4243 mL cartridges300802982810 mL vials10003 mL prefilled pens300Follow-on insulin glargine 100 U/mL \[[@CR31]\]NA243 mL prefilled pens3008025328Insulin glargine 300 U/mL \[[@CR32]\]6241.5 mL prefilled pens450/90080/16029842Insulin degludec 100 or 200 U/mL \[[@CR33]\]1\> 423 mL prefilled pens containing either 100 or 200 U/mL300/600^b^80/160^b^35556Insulin detemir 100 U/mL \[[@CR34]\]0.8--2 \[[@CR48]\]\< 2410 mL vials100080323423 mL prefilled pens300*NA* not available^a^Median cost in the USA calculated as the average wholesale price per 1000 units of a specified dosage^b^At 200 U/mL

NPH Insulin {#Sec4}
-----------

Intermediate-acting NPH insulin shows a pronounced peak effect, which is associated with a high degree of inter- and intra-patient variability and can complicate dose titration and lead to nocturnal hypoglycemia. Moreover, its duration of action is only 12--14 h, which means that many patients will need twice-daily dosing to achieve full 24-h insulin coverage \[[@CR35]\]. Ideally, NPH should be given in the evening/at bedtime in order to improve FPG. Although FPG goals can be achieved in many patients using this approach, the risk of nocturnal hypoglycemia is higher, in part because of absorption variability. A further practical consideration that complicates the use of NPH is that its pen cartridges are in a two-phase solution, requiring adequate mixing to ensure complete resuspension prior to injection; inadequate resuspension of NPH is common and may impair glycemic control \[[@CR36]\]. However, NPH has the advantage of lower costs compared with basal insulin analogs.

U-500 regular insulin, which contains 500 U/mL of Humulin R insulin, is not a true basal insulin but is targeted at patients requiring very large insulin doses. In patients with uncontrolled diabetes and insulin resistance, multiple daily injections result in significant improvements in glycemic control without increased hypoglycemia, but with significantly more weight gain and insulin doses compared with U-100 \[[@CR37]\]. Initial prescriptions for U-500 were written in volume rather than units to avoid dose-conversion errors \[[@CR38]\]. However, a new dispensing pen device that is dosed in units and a US Food and Drug Administration-approved syringe for use with vials do not require dose conversion \[[@CR39]\].

Premixed Insulin Formulations {#Sec5}
-----------------------------

Premixed insulin formulations combine a rapid-acting insulin with a longer-acting insulin. These can be prescribed for both insulin-naive patients and those already receiving insulin who require treatment intensification \[[@CR3]\]. NPH combined with a regular insulin formulation has long been available, but newer formulations of biphasic insulin aspart or insulin lispro have emerged \[[@CR6]\]. Premixed insulin formulations tend to result in greater HbA1c reductions compared with basal insulin \[[@CR40]\]. Additionally, these have the obvious advantage of allowing two insulin formulations to be delivered in a single injection, therefore reducing the number of injections. These formulations, however, tend to be associated with higher rates of hypoglycemia compared with basal insulin and offer reduced dosing flexibility compared with individual treatments \[[@CR41]\].

Basal Insulin Analogs {#Sec6}
=====================

Basal insulin analogs have a longer duration of action than NPH, with a more stable and consistent biologic activity, resulting in more predictable blood glucose levels and a lower risk of hypoglycemia, particularly nocturnal hypoglycemia \[[@CR42]--[@CR44]\]. Compared with NPH, basal insulin analogs have reduced variability in glucose-lowering response \[[@CR45]\]. In addition, the lower incidence of hypoglycemia may be of particular benefit to patients who fear this complication, and may facilitate titration by reducing the tendency to become overcautious when hypoglycemia occurs.

First-Generation Basal Insulin Analogs {#Sec7}
--------------------------------------

### Gla-100 {#Sec8}

Gla-100 was the first basal insulin analog to be approved for use in diabetes and is the most commonly used basal insulin analog worldwide. It has a well-established mode of action, with a less pronounced peak in its time--action profile compared with NPH insulin, an earlier onset of action at around 2--4 h, and a duration of action of around 24 h, allowing for once-daily dosing at a time convenient for the patient. Gla-100 also has a well-established efficacy and safety profile. Compared with NPH insulin, treatment of T2D with Gla-100 results in similar or better glycemic control, but with a significant reduction in nocturnal and overall hypoglycemia with once-daily dosing \[[@CR42]\]. Recently, a follow-on version of insulin glargine received regulatory approval \[[@CR31]\]. This follow-on product showed similar safety and efficacy outcomes, either alone or combined with OADs, in insulin-naive patients and patients previously treated with insulin glargine \[[@CR46], [@CR47]\].

### IDet {#Sec9}

The duration of action of IDet is shorter than that of Gla-100, \< 24 h at therapeutic doses of ≤ 0.3 U/kg in some studies \[[@CR48]\]; because of this, some patients may benefit from divided doses twice daily rather than a single daily injection. Overall, IDet and Gla-100 have similar safety and efficacy, but higher doses of IDet were often needed in clinical trials to achieve similar glycemic effects \[[@CR49]\]. IDet has also shown similarity to NPH in terms of glycemic control, with a lower incidence of hypoglycemia and less weight gain \[[@CR43], [@CR50]\].

Second-Generation Basal Insulin Analogs {#Sec10}
---------------------------------------

The more recently approved Gla-300, IDeg-100, and IDeg-200 provide the advantage of once-daily dosing and a longer duration of action \[[@CR51]--[@CR53]\].

### Gla-300 {#Sec11}

Gla-300 is a formulation of insulin glargine that delivers the same number of insulin units as Gla-100, but in one-third of the injection volume. The pharmacokinetic (PK)/pharmacodynamic (PD) profiles of Gla-300 are more constant and prolonged compared with those of Gla-100, which results in continued blood-glucose control beyond 24 h, with evenly distributed activity \[[@CR51], [@CR54]\]. This allows for more flexibility in timing of dosing and reduces day-to-day variation in blood glucose values. Patients controlled on Gla-100 who switch to Gla-300 are likely to need a higher daily dose to maintain the same level of glycemic control \[[@CR32]\]. In the EDITION 3 clinical trial involving insulin-naive patients, Gla-300 was as effective as Gla-100 at reducing HbA1c, with a lower risk of hypoglycemia, particularly nocturnal hypoglycemia \[[@CR55]\]. Compared with Gla-100, Gla-300 is relatively weight-neutral in patients with T2D, resulting in similar weight gain in patients receiving basal plus mealtime insulin, and significantly less weight gain in patients receiving OADs in addition to basal insulin \[[@CR56]\]. The Gla-300 SoloSTAR pen delivers a maximum dose of 80 U, but in a smaller injection volume. Therefore, patients who require doses \> 80 U/day should split the required dose into two separate injections at the same dosing time or use the SoloSTAR MAX pen, which can deliver up to 160 U in a single injection \[[@CR32]\].

### IDeg {#Sec12}

IDeg-100 is a modified insulin molecule with a duration of action of \> 42 h, a half-life of \> 25 h, and a flat and stable PD profile \[[@CR57], [@CR58]\]. In both insulin-naive and previously insulin-treated patients, IDeg-100 has demonstrated glycemic control similar to that achieved with both Gla-100 and IDet \[[@CR59]\]. IDeg-200 is bioequivalent to IDeg-100, with a similar PD profile at steady state, suggesting interchangeability with IDeg-100 \[[@CR60]\]. In clinical trials, both formulations showed similar glycemic control to Gla-100 in insulin-naive patients, with a lower incidence of nocturnal hypoglycemia, particularly for IDeg-200 \[[@CR53], [@CR61]--[@CR64]\]. In patients with T2D and at least one hypoglycemia risk factor, patients switching to IDeg from Gla-100 experienced reduced rates of overall symptomatic hypoglycemia compared with those switching to Gla-100 from IDeg \[[@CR65]\]. IDeg-200 may reduce injection volumes and improve dosing flexibility compared with first-generation basal insulins. In addition, the IDeg-200 pen can deliver up to 160 U, which may reduce the number of injections needed by people with high-dose insulin requirements. The different PK/PD profiles for longer-acting insulins may have implications for titration.

Treatment Algorithms {#Sec13}
====================

Data from clinical studies evaluating the safety and efficacy of basal insulins in insulin-naive patients provide the basis for recommendations regarding treatment initiation and titration. Key head-to-head studies of insulin initiation vary in terms of treatment goals and schedules (Table [2](#Tab2){ref-type="table"}). In addition to clinical trials, a number of studies have been performed to evaluate different basal insulin algorithms, with varying numbers of steps, different step sizes (i.e., magnitude of increase or decrease in insulin dose), and different titration frequencies, ranging from daily to weekly (Table [3](#Tab3){ref-type="table"}). Considering the data altogether, most trials used a basal insulin starting dose of 10 U/day, with the majority using an FPG target of approximately 100 mg/dL. Most algorithms used weekly or 3-day dose adjustments and titrated insulin on the basis of a mean value from more than one and generally two to three FPG levels over the previous days. Insulin dose steps varied, with some studies using simple 2-U steps and others smaller or larger steps based on blood glucose levels. Final insulin doses varied but were often \> 50 U/day. Irrespective of the algorithm used, the initiation and titration of basal insulin was associated with pronounced improvements in HbA1c, and rates of hypoglycemia were generally low.Table 2Key head-to-head studies of basal-insulin initiation in insulin-naive patientsStudyStudy detailsTargetTitration algorithmTitration frequencyInsulin starting doseInsulin dose at EOSHbA1c,  % baselineHbA1c, % at EOSHypoglycemiaRiddle 2003 \[[@CR42]\]Gla-100 or NPH once daily for 24 weeks*n* = 756≤ 100 mg/dLDose adjustment based on mean of self-monitored FPG values from preceding 2 days: ≥ 180 mg/dL ↑ 8 U insulin; 140--180 mg/dL ↑ 6 U; 120--140 mg/dL ↑ 4 U; 100--120 mg/dL ↑ 2 UWeekly10 UGla-100 47.2 U; NPH 41.8 UGla-100 8.61; NPH 8.56Gla-100 6.96; NPH 6.97Gla-100 9.2/patient year; NPH 12.9/patient yearLANMETYki-Järvinen 2006 \[[@CR66]\]Gla-100 or NPH once daily before bedtime for 36 weeks*n* = 11072--100 mg/dLDose adjustment based on mean pre-breakfast SMPG over 3 consecutive days: \> 100 mg/dL ↑ 2 U; \> 180 mg/dL ↑ 4 UNot stated10 U for patients using metformin alone; 20 U if patients had used both sulfonylurea and metforminGla-100 68 U (0.69 U/kg); NPH 70 U (0.66 U/kg)Gla-100 9.13; NPH 9.26Gla-100 7.14; NPH 7.16Gla-100 5.4/patient year; NPH 8.0/patient yearHermansen 2006 \[[@CR50]\]Insulin detemir or NPH twice daily for 24 weeks*n* = 476≤ 108 mg/dL (pre-breakfast and pre-dinner)Dose adjustment based on average of 3 preceding SMPG levels on consecutive days: \> 180 mg/dL ↑ 10 U (responders and non-responders); 163--180 mg/dL ↑ 6 U (responders) ↑ 8 U (non-responders); 145--162 mg/dL ↑ 4 U (responders) ↑ 6 U (non-responders); 127--144 mg/dL ↑ 2 U (responders) ↑ 4 U (non-responders); 109--126 mg/dL ↑ 2 U (responders and non-responders); if one pre-breakfast plasma glucose: 56--72 mg/dL ↓ 2; \< 56 mg/dL ↓ 4At least weekly for 12 weeks and at least fortnightly thereafter10 U per injectionDetemir 36.1 U pre-breakfast and 29.5 U in the evening; NPH 25.3 U pre-breakfast and 19.7 U in the eveningDetemir 8.6; NPH 8.5Detemir 6.8; NPH 6.6Detemir 8.6/patient year; NPH 15.95/patient yearRosenstock 2008 \[[@CR67]\]Insulin detemir (once or twice daily) or Gla-100 (once daily) for 52 weeks*n *= 582≤ 108 mg/dLDose adjustments in 2-U steps in the evening according to average pre-breakfast SMPG and response to previous dose adjustment; morning dose adjustment according to average pre-dinner SMPG in some insulin detemir patientsDaily12 UDetemir 0.78 U/kg (once daily 0.52 U/kg, twice daily 1.00 U/kg); Gla-100 0.44 U/kgDetemir 8.64; Gla-100 8.62Detemir 7.16 (once daily 7.12, twice daily 7.06); Gla-100 7.12Detemir 5.8/patient year; Gla-100 6.2/patient yearBEGIN ONCE LONGZinman 2012 \[[@CR61]\]IDeg 100 U or Gla-100 100 U once daily for 52 weeksInadequately controlled with OADs*n* = 103070--88 mg/dLDose adjustment on the basis of the average of pre-breakfast SMPG values of 3 consecutive days preceding a visit (full details not given)Not reported10 UIDeg 0.59 U/kg; Gla-100 0.60 U/kg8.2 for bothIDeg 7.1; Gla-100 7.0IDeg 1.52/patient year; Gla-100 1.85/patient yearBEGIN LOW VOLUMEGough 2013 \[[@CR62]\]IDeg 200 U or Gla-100 100 U once daily for 26 weeks*n* = 457\< 90 mg/dLDose adjustment according to the average of 3 consecutive preceding pre-breakfast SMPG levels: \< 56 mg/dL ↓ 4 U; 56--69 mg/dL ↓ 2 U; 70--89 mg/dL no change; 90--125 mg/dL ↑ 2 U; 126--143 mg/dL ↑ 4 U; 144--161 mg/dL ↑ 6 U; ≥ 162 mg/dL ↑ 8 UWeekly10 UIDeg 0.53 U/kg; Gla-100 0.60 U/kgIDeg 8.3; Gla-100 8.2Mean HbA1c decreased by 1.3% in both treatment groupsIDeg 1.22/patient year; Gla-100 1.42/patient yearBEGIN FLEXMeneghini 2013 \[[@CR63]\]IDeg 100 U once-daily in a pre-specified dosing schedule (8--40-h intervals between injections) or IDeg 100 U once-daily IDeg at the main evening meal or Gla-100 at the same time each day for 26 weeksInsulin-naive or -experienced*n* = 61070--90 mg/dLDose adjustment according to the average of 3 consecutive preceding pre-breakfast SMPG levels: \< 56 mg/dL ↓ 4 U; 56--69 mg/dL ↓ 2 U; 70--89 mg/dL no change; 90--125 mg/dL ↑ 2 U; 126--143 mg/dL ↑ 4 U; 144--161 mg/dL ↑ 6 U; ≥ 162 mg/dL ↑ 8  UWeekly10 U in insulin-naive patients0.6 U/kg for all groups in insulin-experienced patients; 0.5 U/kg for all groups in insulin-naive patientsIDeg flexible dosing 8.5;IDeg fixed 8.4; Gla-100 8.4IDeg flexible dosing mean decrease by 1.28; IDeg fixed 1.07; Gla-100 1.26IDeg flexible dosing 3.6/patient year; IDeg fixed 3.6/patient year; Gla-100 3.5/patient yearMeneghini 2013 \[[@CR68]\]Insulin detemir or Gla-100 for 26 weeks*n* = 457≤ 90 mg/dLDose adjustment based on mean of 3 consecutive pre-breakfast SMPG measurements: 92--144 mg/dL ↑ 2 U; for each 18 mg/dL above that range (but ≤ 180 mg/dL), ↑ 2 U, with a maximum of 8 U added if mean FPG was \>180 mg/dL. No dose adjustment was made if mean FPG was \> 71 to ≤ 90 mg/dL, with no value ≤ 71 mg/dL without an obvious explanationThe dose was to be reduced by 2 U if ≥ 1 fasting SMPG readings were 56--71 mg/dL and by 4 U if \< 56 mg/dLWeekly10 UDetemir 57 U (0.7 U/kg); Gla-100 51 U (0.61 U/kg)Detemir 7.96; Gla-100 7.86Detemir 7.48; Gla-100 7.13Detemir 3.19/patient year; Gla-100 4.41/patient yearOnishi 2013 \[[@CR64]\]IDeg or Gla-100 100 U once daily for 26 weeks*n* = 43570--90 mg/dLDose adjustment based on mean of 3 consecutive pre-breakfast SMPG measurements: \< 56 mg/dL ↓ 4 U; 56--69 mg/dL ↓ 2 U; 70--89 mg/dL no change; 90--125 mg/dL ↑ 2 U; 126--143 mg/dL ↑ 4 U; 144--161 mg/dL ↑ 6 U; ≥ 162 mg/dL ↑ 8 UWeekly10 UIDeg 19 U (0.28 U/kg); Gla-100 24 U (0.35 U/kg)IDeg 8.4; Gla-100 8.5IDeg 7.2; Gla-100 7.1IDeg 3.0/patient year; Gla-100 3.7/patient yearBEGIN EASY AM; BEGIN EASY PMZinman 2013 \[[@CR53]\]IDeg 200 U three times weekly, either before breakfast (AM) or with the evening meal (PM), or Gla-100 once daily*n* = 92770--90 mg/dLBased on mean pre-breakfast SMPG (lowest value from prior 3 consecutive days) IDeg: \< 56 mg/dL ↓ 8 U; 56--69 mg/dL ↓ 4 U; 70--89 mg/dL no change; 90--125 mg/dL ↑ 4 U; 126-- 143 mg/dL ↑ 8 U; 144--161 mg/dL ↑ 12 U; ≥ 162 mg/dL ↑ 16 U Gla-100: \< 56 mg/dL ↓ 4U; 56--69 mg/dL ↓ 2 U; 70--89 mg/dL no change; 90--125 mg/dL ↑ 2 U; 126--143 mg/dL ↑ 4 U; 144--161 mg/dL ↑ 6 U; ≥ 162 mg/dL ↑ 8 UWeeklyIDeg 20 U; Gla-100 10 UIDeg AM 50 U; Gla-100 62 UIDeg PM 51 U; Gla-100 56 U(mean calculated dose for IDeg vs actual dose for Gla-100)IDeg AM 8.2; Gla-100 8.3IDeg PM 8.3; Gla-100 8.3IDeg AM mean decrease of 0.93; Gla-100 1.28IDeg PM mean decrease of 1.09; Gla-100 1.35(Confirmed) IDeg AM 1.3/patient year; Gla-100 1.2/patient yearIDeg PM 1.6/patient year; Gla-100 1.0/patient yearEDITION 3Bolli 2015 \[[@CR55]\]Gla-300 or Gla-100 once-daily for 6 months*n* = 87880--100 mg/dLSMPG \> 100 and \< 140 mg/dL ↑ 3 U; SMPG ≥ 140 mg/dL ↑ 6 U; SMPG ≥ 60 and \< 80 mg/dL ↓ 3 U; SMPG \< 60 mg/dL or if severe or multiple symptomatic hypoglycemia events occurred ↓ ≥ 3 U at investigator's discretionWeekly0.2 U/kg/dayGla-300 0.62 U/kg; Gla-100 0.53 U/kgGla-300 8.49; Gla-100 8.58Gla-300 7.08; Gla-100 7.05≥ 1 confirmed (≤ 3.9 mmol/L) or severe hypoglycemia event: Gla-300 46%; Gla-100 53%*EOS* end of study, *FPG* fasting plasma glucose, *Gla*-*100* insulin glargine 100 U/mL, *Gla*-*300* insulin glargine 300 U/mL, *HbA1c* glycated hemoglobin A1c, *IDeg* insulin degludec, *Gla*-*100* insulin glargine, *NPH* neutral protamine Hagedorn insulin, *SMPG* self-monitored plasma glucoseTable 3Titration trials of insulin initiation in insulin-naive patientsStudyTreatmentTitration goalTitration algorithmTitration frequencyInsulin starting doseInsulin dose at EOSHbA1c,  % baselineHbA1c,  % EOSHypoglycemia (overall confirmed events)AT.LANTUSDavies 2005 \[[@CR69]\]Gla-100 once daily for 24 weeks. Suboptimally controlled on insulin or OADs*n* = 4961≤ 100 mg/dLBased on mean of self-monitored FPG values from preceding 3 consecutive days Algorithm 1: ≥ 180 mg/dL ↑ 6--8 U insulin; 140--180 mg/dL ↑ 4 U; 120--140 mg/dL ↑ 2 U; ≥ 100--120 mg/dL ↑ 0--2 UAlgorithm 2: ≥ 180 mg/dL ↑ 2 U insulin; 140--180 mg/dL ↑ 2 U; 120--140 mg/dL ↑ 2 U; ≥ 100--120 mg/dL ↑ 0--2 UAlgorithm 1: titration weekly; managed by physicianAlgorithm 2: titration every 3 days; managed by patientVarious depending on prior treatmentReported in figure onlyAlgorithm 1 8.9; algorithm 2 8.9Algorithm 1 7.9; algorithm 2 7.7Algorithm 1 29.8%; algorithm 2 33.3%GOAL A1CKennedy 2006 \[[@CR70]\]Gla-100 once daily for 24 weeks*n* = 789370--100 mg/dLAlgorithm 1: usual titration of Gla-100 and laboratory HbA1c testing; algorithm 2: usual titration and POC HbA1c testing; algorithm 3: active titration and laboratory HbA1c testing; algorithm 4: active titration and POC HbA1c testing"Usual titration" defined as patient instruction at study visits every 6 weeks only (patient managed)"Active titration" defined as additional weekly patient contact (telephone, email, or fax) to reinforce insulin titrationBased on mean fasting SMPG: insulin was increased by SMPG ≥ 100 to \< 120 mg/dL ↑ 0--2 U; ≥ 120 to \< 140 mg/dL ↑ 2; 140 to \< 160 mg/dL ↑ 4; ≥ 160 to \< 180 mg/dL ↑ 6; ≥ 180 mg/dL ↑ 8. If \< 70 mg/dL ↓ previous lower dose. If severe hypoglycemia (e.g., SMPG \< 36 mg/dL) occurred, upward titration was stopped for 1 week. If the HbA1c was \> 8.0% after visit 1, Gla-100 dose could be increased, at the investigator's discretion, by up to 5 additional units to meet glycemic targets at each subsequent study visitWeekly10 UUsual titration groups 50 U; active titration groups 55--56 UUsual titration groups 8.9; active titration groups 8.8--8.9Usual titration groups 7.6; active titration groups 7.3Usual titration groups 3.7/patient year; active titration groups 6.0/patient yearPREDICTIVE 303Meneghini 2007 \[[@CR71]\]Insulin detemir for 26 weeks*n *= 5604≤ 100 mg/dLAlgorithm 1 (patient-adjusted): Based on average of 3 fasting SMPG \< 80 mg/dL, ↓ 3 U; 80--110 mg/dL, no change; \> 110 mg/dL ↑ 3 UAlgorithm 2 (physician adjusted): according to standard of care (variable)Algorithm 1: every 3 days; algorithm 2: according to standard of care (variable)On day 1: Algorithm 1 0.32 U/kg; algorithm 2 0.34 U/kgAlgorithm 1 0.68 U/kg; algorithm 2 0.53 U/kgAlgorithm 1 8.5; algorithm 2 8.5Algorithm 1 7.9; algorithm 2 8.0Algorithm 1 6.44/patient year; algorithm 2 4.95/patient yearTITRATEBlonde 2009 \[[@CR72]\]Insulin detemir once daily for 2 weeks*n* = 24470--90 or 80--110 mg/dL (3.9--5.0 or 4.4--6.1 mmol/L)Using 3.9--5.0 mmol/L target: \< 3.9 mmol/L ↓ 3 U; 3.9--5.0 mmol/L no adjustment; \> 5.0 mmol/L ↑ 3 UUsing 4.4--6.1 mmol/L target: \< 4.4 mmol/L ↓ 3 U; 4.4--6.1 mmol/L no adjustment; \> 6.1 mmol/L ↑ 3 UEvery 3 days0.1--0.2 U/kg or 10 U3.9--5.0 mmol/L treatment group 0.57 U/kg; 4.4--6.1 mmol/L group 0.51 U/kg3.9--5.0 mmol/L treatment group 7.99; 4.4--6.1 mmol/L group 7.943.9--5.0 mmol/L treatment group 6.77; 4.4--6.1 mmol/L group 7.003.9--5.0 mmol/L treatment group 7.73/patient year; 4.4--6.1 mmol/L group 5.27/patient yearBEGIN: OncePhilis-Tsimikas 2013 \[[@CR73]\]Simple useIDeg 100 U for 26 weeks*n* = 222"Simple" algorithm: 4-U dose adjustments based on a single pre-breakfast SMPG measurement; \< 56 mg/dL ↓ 4 U; \> 91 mg/dL ↑ 4 U)."Stepwise" algorithm: 2-U adjustments based on the lowest of 3 consecutive pre-breakfast SMPG readings (\< 56 mg/dL ↓ 4 U; 56--70 mg/dL ↓ 2 U; 91--126 mg/dL ↑ 2 U; 127--144 mg/dL ↑ 4 U; 145--162 mg/dL ↑ 6 U; \> 162 mg/dL ↑ 8 UWeekly10 U"Simple" 62 U (0.61 U/kg);"Stepwise" 48 U (0.50 U/kg)"Simple" 8.1; "Stepwise" 8.2"Simple" 7.0; "Stepwise" 7.2"Simple" 1.60/patient year; "Stepwise" 1.17/patient yearDailey 2014 \[[@CR74]\]Gla-100 once daily for 24 weeks (pooled analysis of patient-level data from RCTs)*n* = 1380≤ 100 mg/dL, with some studies also specifying a target FPG ≥ 72 mg/dLAlgorithm 1: ↑ 1 U once daily, if FPG \> target; algorithm 2: ↑ 2 U every 3 days, if FPG \> target; algorithm 3: treat-to-target, weekly titration based on 2-day mean FPG levels: ≥ 180 mg/dL ↑ 8 U; 140--180 mg/dL ↑ 6 U; 120--140 mg/dL ↑ 4 U; 100--120 mg/dL ↑ 2 UDose decreases (2--4 U/day) were allowed if severe hypoglycemia (requiring assistance) or plasma glucose \< 56 mg/dL at any time in the preceding weekOnce daily; once every 3 days; once weekly10 UAlgorithm 1 0.42 U/kg; algorithm 2 0.56 U/kg; algorithm 3 0.42 U/kgAlgorithm 1 8.61; algorithm 2 8.79; algorithm 3 8.84Algorithm 1 7.11; algorithm 2 7.02; algorithm 3 7.05Algorithm 1 4.03/year; algorithm 2 1.58/year; algorithm 3 6.5/yearLANCELOTHome 2015 \[[@CR75]\]Gla-100 or NPH for 36 weeks*n* = 70180--100 mg/dL (4.4--5.5 mmol/L) for both fasting and nocturnal levelsTitration based on both pre-breakfast FPG levels (median previous 3 measures) and last nocturnal SMPG levelNocturnal and/or fasting ≤ 4.4 mmol/L or symptomatic hypoglycemia ↓ 2 U; nocturnal \> 4.4 to ≤ 5.5 mmol/L and fasting \> 4.4 mmol/L no change; fasting \> 4.4 to ≤ 5.5 mmol/L and nocturnal \> 4.4 mmol/L no change; nocturnal and fasting \> 5.5 to ≤ 7.8 mmol/L ↑ 2 U; fasting \> 5.5 to ≤ 7.8 mmol/L and nocturnal \> 7.8 mmol/L ↑ 2 U; nocturnal \> 5.5 to ≤ 7.8 mmol/L and fasting \> 7.8 mmol/L ↑ 2 U; nocturnal and fasting \> 7.8 mmol/L ↑ 4 U. In the event of severe hypoglycemia or HbA1c ≤ 6.0%, no insulin dose increase was allowed for the remainder of the studyWeekly during weeks 1--4, twice weekly during weeks 5--12, weekly up to week 360.2 U/kgGla-100 32.4 U (0.39 U/kg); NPH 30.7 U (0.36 U/kg)8.2 for bothGla-100 7.1; NPH 7.2Gla-100 1.74 patient year; NPH 2.21 patient yearYale 2016 \[[@CR76]\]^a^Gla-300 titrated using the EDITION or INSIGHT protocols*n* = 21280--100 mg/dLEDITION: SMPG \> 100 and \< 140 mg/dL ↑ 3 U; SMPG ≥ 140 mg/dL ↑ 6 U; SMPG ≥ 60 and \< 80 mg/dL ↓ 3 U; SMPG \< 60 mg/dL or if severe or multiple symptomatic hypoglycemia events occurred ↓ ≥ 3 U at investigator's discretionINSIGHT: 1 U/day until in target rangeEDITION: weeklyINSIGHT: dailyEDITION: 70.0 UINSIGHT: 67.0 UEDITION: 8.4INSIGHT 8.4EDITION: 7.6INSIGHT: 7.6EDITION: 48.1%INSIGHT: 55.6%*EOS* end of study, *FPG* fasting plasma glucose, *Gla*-*100* insulin glargine 100 U/mL, *Gla*-*300* insulin glargine 300 U/mL, *HbA1c* glycated hemoglobin A1c, *IDeg* insulin degludec, *Gla*-*100* insulin glargine, *NPH* neutral protamine Hagedorn insulin, *OAD* oral antidiabetes drug, *POC* point of care, *RCT* randomized controlled trial, *SMPG* self-monitored plasma glucose^a^Insulin-naive: EDITION 32.7%, INSIGHT 37.0%

Overall, no particular algorithm has been consistently shown to have greater clinical benefits over the others. However, a key consideration in algorithm design is that titration must be manageable and should support healthcare professionals and patients in optimizing basal insulin therapy; simpler algorithms may therefore be preferable and also result in improved clinical outcomes. For example, a pooled analysis of patient-level data from randomized controlled clinical trials found that, although three different algorithms for initiation and titration of Gla-100 in patients with T2D resulted in similar levels of glycemic control, lower rates of hypoglycemia were seen in patients treated using simpler algorithms (standard dose increase either once a day or every 3 days if FPG was above target) compared with a more complex once-weekly, treat-to-target algorithm \[[@CR74]\].

The use of simple titration algorithms may allow patients, under the direction and support of a healthcare provider, including their pharmacist, to adjust their own insulin dose, which could lead to fewer clinic visits and improve patients' comfort and confidence/acceptance of their insulin regimen \[[@CR74]\]. In some studies, simple patient-driven titration algorithms for insulin initiation have been shown to be as effective as physician-driven regimens, achieving similar or better glycemic control, with generally low rates of hypoglycemia \[[@CR71], [@CR72]\]. However, there is evidence that, at least with more complex titration algorithms, regular support can improve glycemic control \[[@CR70]\].

A number of organizations have produced algorithms for the initiation, titration, and intensification of basal insulin therapy \[[@CR2]--[@CR6]\]. Although similar in many respects, they vary in terms of insulin titration schedules and targets (Table [4](#Tab4){ref-type="table"}). When considering these recommendations, it is important to remember that what works well for one patient may not be optimal for others. Basal insulin therapy typically starts at a low dose (10 U or 0.1--0.2 U/kg/day) depending on the degree of hyperglycemia \[[@CR6]\], but patients should be made aware that this is still a safe starting point and that further titration will be needed. The simplest and most convenient strategy for basal insulin initiation is a single injection at a time chosen to best fit the patients' preferences and their overall glucose profiles \[[@CR6]\]. While several algorithms have been used in clinical trials, the majority recommends small dose increases (e.g., ≥ 2--4 U in patients taking higher doses) once- or twice-weekly if FPG levels are above the pre-agreed target (Table [4](#Tab4){ref-type="table"}). This is considered a reasonable approach by several treatment guidelines \[[@CR3], [@CR5], [@CR6]\], although a more complicated "adjustable" (treat-to-target) algorithm is also recommended \[[@CR5]\].Table 4Comparison of guideline recommendations for initiation and titration of basal insulin in T2DGuidelineADA \[[@CR6]\]AACE/ACE \[[@CR5]\]IDF \[[@CR3]\]Initial dose10 U or 0.1--0.2 U/kg/day^a^HbA1c \< 8%: 0.1--0.2 U/kg/dayHbA1c \> 8%: 0.2--0.3 U/kg/dayNot specifiedTitration Target FPG4.4--7.2 mmol/L (80--130 mg/dL), but individualize to patient/disease features^b^\< 6.1 mmol/L (\< 110 mg/dL)\< 6.5 mmol/L (\< 115 mg/dL) Target HbA1cUsually \< 7%, but individualize to patient/disease features^b^\< 7% for most patients^c^Generally \< 7% Dose changeAdd 10--15% or 2--4 UFixed regimen: 2 UAdjustable regimen: FPG \> 180 mg/dL: add 20% of TDDFPG 140--180 mg/dL: add 10% of TDDFPG 110--139 mg/dL: add 1 UAdd 2 U FrequencyOnce- to twice-weeklyEvery 2--3 daysEvery 3 days HypoglycemiaReduce dose by 4 U or 10--20% of TDDReduce TDD by:BG \< 70 mg/dL: 10--20%BG \< 40 mg/dL: 20--40%Not specifiedEscalate to combination injectablesConsider when FPG is ≥ 300 mg/dL (≥ 16.7 mmol/L) or HbA1c ≥ 10%When targets are not achievedNot specified*AACE/ACE* American Association of Clinical Endocrinologists/American College of Endocrinology, *ADA* American Diabetes Association, *BG* blood glucose, *FPG* fasting plasma glucose, *HbA1c* glycated hemoglobin A1c, *IDF* International Diabetes Federation, *T2D* type 2 diabetes, *TDD* total daily dose^a^Depending on the degree of hyperglycemia^b^Goals should be individualized on the basis of duration of diabetes, age/life expectancy, comorbid conditions, known cardiovascular disease or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations^c^AACE/ACE guidelines state that HbA1c levels of ≤ 6.5% are optimal if they can be achieved in a safe and affordable manner, but patients using insulin are considered to not be achieving glycemic control and are therefore advised to intensify therapy if HbA1c ≥ 7%

As with all aspects of patient care in T2D, the choice of optimal titration schedule should be personalized to the status, needs, and preferences of the patient. More frequent dose adjustments (e.g., daily) have generally not been recommended because day-to-day FPG levels vary by around 15%, with the largest variations in patients with higher FPG values \[[@CR77]\]. As patients approach their target FPG, smaller and less frequent dose adjustments reduce the risk of hypoglycemia \[[@CR2]\]. During titration, the insulin dose should be reduced if any hypoglycemia occurs \[[@CR6]\]. Reinforcement of patients' understanding of hypoglycemia (e.g., why it happens, how best to avoid it, how to manage it) and decisions as to the possible impact of hypoglycemia on the titration schedules are important aspects of successful management. Once patients achieve a stable dose of insulin, the frequency of monitoring should be reviewed \[[@CR2]\]. In pivotal trials of basal insulins, final doses varied widely but were often \> 50 U, so it is important not to abandon basal insulin titration and intensify therapy too early. However, it is equally important not to continue to increase the basal insulin dose beyond the point at which it is effective at controlling FPG.

The Problem of "Over-Basalization" {#Sec14}
----------------------------------

One of the major challenges faced with longer-term use of basal insulins is overuse, often referred to as "over-basalization," which occurs when basal insulin continues to be uptitrated in order to compensate for mealtime excursions when the addition of a mealtime bolus would be a better option. Because titration algorithms often do not give an upper limit for basal insulin, it may be tempting to increase the dose in an attempt to meet treatment goals. However, recent studies have shown that FPG reduction becomes proportionally smaller with increasing dose of basal insulin beyond a certain dose level, with a "ceiling effect" at around 0.5 U/kg/day, above which FPG response does not increase substantially despite increasing insulin levels \[[@CR39]\]. FPG is particularly elevated with late and large evening meals, which leads to higher doses of basal insulin and increased hypoglycemia and weight gain; smaller portions in the evening are thus preferable during titration \[[@CR78]\]. Pharmacists may ask patients if hypoglycemia occurs when meals are skipped or in the middle of the night, when basal insulins usually reach their peak effect, which may help avoid over-basalization.

Awareness of the diminishing returns of further increasing basal insulin and the potential benefits of introduction of other therapies at this stage are key to avoiding over-basalization. Pharmacists can aid physicians in identifying patients for whom intensification of treatment may be beneficial and by educating patients on additional medications they have been prescribed, including usage and potential side effects, which may help with patient reluctance to start a new treatment.

A Special Note on Initiation and Titration of the Newer Basal Insulins {#Sec15}
----------------------------------------------------------------------

The current T2D management guidelines were drawn up before the newer longer-acting basal insulins were available. Owing to differences in their formulation and PK/PD profiles, the recommended titration algorithms may not be appropriate for these newer agents. In the BEGIN LOW VOLUME and BEGIN EASY clinical trials of IDeg-200 in insulin-naive patients, treatment was initiated at 10 or 20 U, with either daily or thrice-weekly dosing and once-weekly dose adjustments made according to a multistep, treat-to-target algorithm (Table [2](#Tab2){ref-type="table"}) \[[@CR53], [@CR62]\]. However, prescribing information recommends a similar regime for both IDeg-100 and IDeg-200, with a starting dose of 10 U in insulin-naive patients, daily dosing, and dose adjustments every 3--5 days, with no recommended algorithm. Gla-300 was compared with Gla-100 in insulin-naive patients in the EDITION 3 trial \[[@CR55]\]; the starting dose for both insulins was 0.2 U/kg/day, with weekly dose adjustments based on a simplified treat-to-target algorithm (Table [2](#Tab2){ref-type="table"}). Gla-300 prescribing information recommends a starting dose of 0.2 U/kg/day and dose adjustments no more frequently than every 3--4 days to minimize the risk of hypoglycemia.

The optimal titration schedules for these longer-acting insulins are unknown as no comparative titration algorithm data have been published to date. However, given their longer duration of action, less aggressive titration, in which the basal insulin is titrated no more frequently than every 3 days and possibly less frequently, may be required. In addition, although both Gla-300 and IDeg-200 reduced the risk of hypoglycemia compared with Gla-100, a head-to-head clinical trial of Gla-300 and IDeg in patients with T2D showed lower hypoglycemia event rates for Gla-300 in the 12-week titration period, but they are similar in the maintenance phase (BRIGHT) \[[@CR79]\].

Summary {#Sec16}
=======

A significant proportion of people with diabetes are failing to meet their glycemic targets, putting them at risk of increased morbidity and mortality. While there are likely to be multiple reasons for this, clinical inertia is a key issue, particularly when moving from OADs to insulin therapy and, once insulin is started, to a titrated dose that reaches the goal FPG. As with all aspects of care for people with diabetes, individualization of basal insulin initiation and titration within the context of the needs, preferences, and lifestyle of the patient is essential. Although a number of different titration algorithms have been used and compared in clinical trials, none have proven to be significantly superior to the others. Simpler dosing and titration regimens, as recommended by treatment guidelines, may be of benefit; however, these should be individualized to suit the patient and may need adjustment, depending on the basal insulin prescribed. Digital applications that provide dose-adjusting algorithms can be used together with a variety of treatment plans and dosage guidelines, based on the patient's personalized treatment plan, to support the management of adult patients with T2D treated with basal insulin. These applications can be designed to share the data automatically with the patient's healthcare team, implying that there are multiple points of care at which providers can work with the patient toward his or her goal \[[@CR80]\]. Even with the availability of such technology, pharmacists are still in a unique position to provide support to patients during insulin titration, when clinical inertia is an issue, and when other issues such as "over-basalization" and poor treatment adherence are suspected. As a regular point of contact for the patient and other healthcare providers, the pharmacist is well positioned to identify areas of unmet need for the individual patient, in particular for those taking mixed regimens or rapid-acting insulins who experience frequent hypoglycemia episodes or glucose excursions, and/or those with a lower education level or living in rural areas with fewer resources. With the increasing footprint of digital technologies in day-to-day healthcare, the pharmacy may become a centralized hub through which the interpersonal relationship between the pharmacist and the patient in collaboration with the primary or specialist healthcare provider affords a bridge to the patient's data and contributes to improved diabetes care.
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